Whitehawk Therapeutics to Participate in H.C. Wainwright HCW@Home Series

Published: 2025-06-20 11:04:09 ET WHWK

Published on 06/20/2025 at 11:04

MORRISTOWN - Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced that Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright 'HCW@Home' series on Thursday, June 26, 2025, at 10 AM ET.

To register in advance, please use this link. A live webcast of the event can be accessed by visiting the 'Investors & News' page on the Whitehawk Therapeutics website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics

Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.

Contact:

Email: [email protected]